Adrian Subrt, MD
Dermatology · Katy, TXNPI 1386055382
Payments from drug & device makers
Across 225 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arcutis Biotherapeutics, Inc.$3K
- AbbVie$1K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$412
- Lilly USA, LLC$294
- Galderma Laboratories, L.p.$176
- plus $627 from 8 others
What the payments were for
- Consulting fees$1,65025%
- Travel & lodging$5508%
- Food & beverage$4,14163%
- Education$2574%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | 39 | $2,761 |
| AbbVie | 80 | $1,249 |
| Johnson & Johnson | 55 | $1,079 |
| E.r. Squibb & Sons, L.L.C. | 13 | $412 |
| Lilly USA, LLC | 11 | $294 |
| Galderma Laboratories, L.p. | 5 | $176 |
| UCB, Inc. | 6 | $123 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Sanofi | 4 | $121 |
| Amgen | 6 | $118 |
| Sun Pharmaceutical Industries Inc. | 2 | $70 |
| Organon | 1 | $35 |
| Pfizer | 1 | $20 |
| Verrica Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,597 in reported general payments places this provider in the 55th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 11 | $72,117 |
| Dupixent PenDupilumab | 13 | $49,675 |
| Clobetasol Propionate | 263 | $10,599 |
| Metronidazole | 73 | $7,142 |
| Fluocinonide | 156 | $6,222 |
| Tacrolimus | 30 | $4,886 |
| Doxycycline Monohydrate | 124 | $3,851 |
| Ketoconazole | 208 | $2,932 |
| Alclometasone Dipropionate | 72 | $2,853 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 59 | $2,682 |
| Azelaic Acid | 29 | $2,143 |
| Desonide | 28 | $2,070 |
| Clindamycin Phosphate | 72 | $1,982 |
| Triamcinolone Acetonide | 149 | $1,681 |
| ValacyclovirValacyclovir Hcl | 69 | $1,531 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Katy
- Uyen Ngoc MuiKaty$329K
- Stephen TyringWebster$14.1M
- Edward LainAustin$12M
- Mark LeeSan Antonio$10.9M
- John BrowningSan Antonio$10.7M
- Craig TellerBellaire$7.7M
- Patricia LeeWebster$7.2M
- Jennifer CatherDallas$4.9M
- Michael MigdenHouston$3.7M
- Martin MenterDallas$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.